Abbott Laboratories Company Insiders

ABT Stock  USD 118.95  0.99  0.84%   
Slightly above 67% of Abbott Laboratories' corporate insiders are selling. The analysis of insiders' sentiment of trading Abbott Laboratories stock suggests that many insiders are alarmed at this time. Abbott Laboratories employs about 114 K people. The company is managed by 49 executives with a total tenure of roughly 322 years, averaging almost 6.0 years of service per executive, having 2326.53 employees per reported executive.
Robert Ford  CEO
President, Chief Executive Officer, Chief Operating Officer, Director
Miles White  Chairman
Chairman, CEO and Chairman of Executive Committee

Abbott Laboratories' Insider Buying Vs Selling

33

 
Selling
 
Buying

Latest Trades

2024-09-12Robert B FordDisposed 141679 @ 116.41View
2024-09-04John JamesDisposed @ 114.4
2024-08-19Josh GottheimerAcquired @ 111.91
2024-07-29Josh GottheimerAcquired @ 104.78
2024-07-23Thomas H. Kean, Jr.Acquired @ 103.92
2024-07-05Jared MoskowitzAcquired @ 104.02
2024-07-02Kathy E. ManningAcquired @ 103.2
2024-05-10Jr. Robert E FunckDisposed 10097 @ 104.57View
2024-05-07Lisa D EarnhardtDisposed 22852 @ 106.25View
2024-03-01Daniel Gesua Sive SalvadoriDisposed 963 @ 118.5View
2024-02-23Andrea F WainerDisposed 12500 @ 120View
2024-01-29Andrea F WainerDisposed 42500 @ 112.5View
2024-01-23Kathy E. ManningDisposed @ 114
2024-01-17Thomas R. CarperDisposed @ 113.96
2023-12-14Andrea F WainerDisposed 15000 @ 108View
Monitoring Abbott Laboratories' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Abbott Laboratories' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Abbott Laboratories. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Abbott Laboratories' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abbott Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
For more information on how to buy Abbott Stock please use our How to Invest in Abbott Laboratories guide.

Abbott Laboratories' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Abbott Laboratories' future performance. Based on our forecasts, it is anticipated that Abbott will maintain a workforce of slightly above 114000 employees by December 2024.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Abbott Laboratories' latest congressional trading

Congressional trading in companies like Abbott Laboratories, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Abbott Laboratories by those in governmental positions are based on the same information available to the general public.
2024-09-18Representative Michael McCaulAcquired $50K to $100KVerify
2024-09-11Representative Josh GottheimerAcquired Under $15KVerify
2024-09-06Representative John JamesAcquired Under $15KVerify
2024-09-02Representative John JamesAcquired Under $15KVerify
2024-08-21Representative Jared MoskowitzAcquired Under $15KVerify
2024-08-19Representative Jared MoskowitzAcquired Under $15KVerify
2024-08-16Representative Kathy ManningAcquired Under $15KVerify
2024-08-15Representative Josh GottheimerAcquired Under $15KVerify
2024-02-02Senator Thomas R CarperAcquired Under $15KVerify
2024-02-01Senator Thomas R CarperAcquired Under $15KVerify
2023-11-01Senator Markwayne MullinAcquired Under $15KVerify
2023-10-31Senator Markwayne MullinAcquired Under $15KVerify
2023-10-20Senator Pete RickettsAcquired $100K to $250KVerify
2023-10-12Senator Markwayne MullinAcquired $15K to $50KVerify
2022-08-13Representative Dean PhillipsAcquired Under $15KVerify
2022-01-27Representative Michael C BurgessAcquired Under $15KVerify
2019-04-24Senator Tina SmithAcquired $250K to $500KVerify
2019-04-23Senator Tina SmithAcquired $250K to $500KVerify
2018-05-05Representative Pete SessionsAcquired Under $15KVerify
2015-08-03Senator Shelley Moore CapitoAcquired Under $15KVerify
2015-08-02Senator Shelley Moore CapitoAcquired Under $15KVerify

Abbott Laboratories Management Team Effectiveness

The company has Return on Asset of 0.0649 % which means that on every $100 spent on assets, it made $0.0649 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1484 %, implying that it generated $0.1484 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024.
Net Income Applicable To Common Shares is likely to gain to about 8.4 B in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 1.3 B in 2024.

Abbott Laboratories Workforce Comparison

Abbott Laboratories is rated second in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 468,000. Abbott Laboratories totals roughly 114,000 in number of employees claiming about 24% of equities under Health Care industry.

Abbott Laboratories Profit Margins

The company has Net Profit Margin of 0.14 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.19 %, which entails that for every 100 dollars of revenue, it generated $0.19 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.620.5518
Moderately Up
Pretty Stable
Net Profit Margin0.150.1427
Sufficiently Up
Very volatile
Operating Profit Margin0.210.1615
Significantly Up
Pretty Stable
Pretax Profit Margin0.210.1661
Significantly Up
Pretty Stable
Return On Assets0.120.0782
Way Up
Very volatile
Return On Equity0.260.1483
Way Up
Very volatile

Abbott Laboratories Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abbott Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abbott Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Abbott Laboratories insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
0.25
1
4
 157,421 
 314,842 
2024-09-01
0.75
6
8
 142,668 
 284,380 
2024-06-01
4.75
19
4
 48,238 
 43,315 
2024-03-01
1.2273
27
22
 1,053,564 
 190,315 
2023-12-01
1.25
5
4
 16,023 
 80,000 
2023-09-01
0.8333
10
12
 31,608 
 85,956 
2023-06-01
4.2
21
5
 60,705 
 74,452 
2023-03-01
1.122
46
41
 1,621,195 
 165,915 
2022-12-01
1.6
8
5
 1,942 
 65,421 
2022-09-01
0.6875
11
16
 127,641 
 390,359 
2022-06-01
2.0909
23
11
 67,642 
 149,379 
2022-03-01
1.2083
58
48
 2,375,058 
 251,024 
2021-12-01
0.48
24
50
 440,718 
 1,105,201 
2021-09-01
0.8077
21
26
 305,674 
 579,836 
2021-06-01
1.5714
22
14
 168,725 
 244,712 
2021-03-01
0.9375
60
64
 2,895,472 
 986,184 
2020-12-01
1.1818
13
11
 171,076 
 286,933 
2020-09-01
0.4583
11
24
 225,482 
 461,654 
2020-06-01
1.1429
32
28
 442,677 
 675,358 
2020-03-01
0.8507
57
67
 3,877,676 
 1,676,057 
2019-12-01
0.4444
4
9
 16,959 
 58,383 
2019-09-01
0.6
12
20
 290,678 
 443,843 
2019-06-01
1.3
52
40
 1,874,831 
 2,900,820 
2019-03-01
0.2027
59
291
 4,353,816 
 2,899,476 
2018-12-01
0.0676
5
74
 391,185 
 797,682 
2018-09-01
0.0984
12
122
 335,500 
 745,101 
2018-06-01
1.2778
23
18
 139,547 
 57,471 
2018-03-01
0.3958
114
288
 5,292,299 
 1,761,436 
2017-12-01
0.0843
15
178
 738,591 
 1,578,706 
2017-09-01
0.6
27
45
 1,085,721 
 1,240,503 
2017-06-01
0.9333
28
30
 482,483 
 426,674 
2017-03-01
0.8214
69
84
 6,435,881 
 1,264,072 
2016-12-01
33.0
165
5
 432,527 
 48,864 
2016-09-01
6.7619
142
21
 1,451,358 
 928,993 
2016-06-01
1.5
21
14
 67,678 
 62,773 
2016-03-01
0.6849
50
73
 7,484,727 
 544,250 
2015-12-01
0.5625
9
16
 441,362 
 952,910 
2015-09-01
0.5385
7
13
 76,866 
 132,908 
2015-06-01
1.0
24
24
 480,134 
 138,279 
2015-03-01
0.3592
37
103
 3,355,163 
 450,749 
2014-12-01
1.3333
12
9
 449,921 
 889,528 
2014-09-01
1.625
13
8
 221,346 
 197,061 
2014-06-01
1.8571
13
7
 59,246 
 57,559 
2014-03-01
0.6923
36
52
 2,576,964 
 356,144 
2013-12-01
0.2903
18
62
 366,337 
 727,860 
2013-09-01
1.2
6
5
 264,503 
 17,993 
2013-06-01
1.1667
14
12
 190,587 
 131,836 
2013-03-01
0.7755
38
49
 3,820,644 
 1,116,549 
2012-12-01
0.3226
30
93
 905,506 
 1,573,525 
2012-09-01
0.3333
31
93
 449,538 
 716,621 
2012-06-01
0.2727
21
77
 168,058 
 295,464 
2012-03-01
0.3035
61
201
 2,294,158 
 1,784,012 
2011-12-01
0.0754
23
305
 1,277,617 
 2,491,533 
2011-09-01
0.3333
6
18
 4,371 
 27,954 
2011-06-01
0.1203
16
133
 51,537 
 293,863 
2011-03-01
0.2927
36
123
 1,599,018 
 507,838 
2010-12-01
0.44
11
25
 36,377 
 112,222 
2010-09-01
0.3235
11
34
 119,723 
 81,620 
2010-06-01
0.4118
14
34
 44,997 
 125,590 
2010-03-01
0.3443
63
183
 1,898,904 
 837,459 
2009-12-01
0.337
31
92
 410,131 
 821,439 
2009-09-01
1.6667
5
3
 16,432 
 36,086 
2009-06-01
1.0833
13
12
 25,848 
 77,067 
2009-03-01
0.343
83
242
 2,773,753 
 1,725,305 
2008-12-01
1.3846
18
13
 15,690 
 31,855 
2008-09-01
0.6989
65
93
 2,356,069 
 2,567,373 
2008-06-01
0.8039
41
51
 247,756 
 228,464 
2008-03-01
0.4029
83
206
 2,857,891 
 1,505,093 
2007-12-01
0.973
36
37
 426,835 
 515,440 
2007-09-01
0.4976
102
205
 3,706,478 
 4,578,169 
2007-06-01
1.2143
17
14
 51,854 
 92,713 
2007-03-01
0.8068
142
176
 4,811,581 
 2,820,938 
2006-12-01
0.4211
8
19
 37,604 
 44,993 
2006-09-01
0.9231
36
39
 845,791 
 906,297 
2006-06-01
0.6774
21
31
 175,617 
 162,010 
2006-03-01
0.8169
58
71
 2,606,390 
 743,051 
2005-12-01
0.4444
4
9
 1,711 
 29,564 
2005-09-01
1.3333
4
3
 1,590 
 38,121 
2005-06-01
1.7692
23
13
 162,714 
 93,191 
2005-03-01
1.1053
42
38
 2,266,181 
 1,292,492 
2004-12-01
0.8125
26
32
 162,717 
 218,438 
2004-09-01
0.7
7
10
 87,786 
 109,476 
2004-06-01
1.5
18
12
 81,865 
 63,792 
2004-03-01
1.1111
30
27
 1,355,904 
 561,185 
2003-12-01
0.5263
10
19
 196,053 
 117,752 
2003-09-01
0.7778
7
9
 133,025 
 141,205 
2003-06-01
0.6667
2
3
 12,367 
 36,651 
2003-03-01
0.0909
1
11
 15,266 
 180,783 

Abbott Laboratories Notable Stakeholders

An Abbott Laboratories stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Abbott Laboratories often face trade-offs trying to please all of them. Abbott Laboratories' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Abbott Laboratories' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert FordPresident, Chief Executive Officer, Chief Operating Officer, DirectorProfile
Miles WhiteChairman, CEO and Chairman of Executive CommitteeProfile
Roger BirdSenior Vice President - U.S. NutritionProfile
Hubert AllenExecutive Vice President, General Counsel, SecretaryProfile
Jared WatkinSenior Vice President - Diabetes CareProfile
Jaime ContrerasSenior Vice President - Core Laboratory Diagnostics, Commercial OperationsProfile
Andrew LaneSenior Vice President - Established Pharmaceuticals, Emerging MarketsProfile
John CapekExecutive Vice President - VenturesProfile
Joseph ManningSenior Vice President - Abbott Nutrition InternationalProfile
Robert FunckChief Financial Officer, Executive Vice President - FinanceProfile
Daniel SalvadoriSenior Vice President - Established Pharmaceuticals, Latin America.Profile
Samuel ScottIndependent DirectorProfile
Phebe NovakovicIndependent DirectorProfile
Roxanne AustinIndependent DirectorProfile
Sally BlountIndependent DirectorProfile
Daniel StarksIndependent DirectorProfile
Robert AlpernIndependent DirectorProfile
Glenn TiltonIndependent DirectorProfile
Darren McDewIndependent DirectorProfile
Patricia GonzalezIndependent DirectorProfile
Nancy McKinstryIndependent DirectorProfile
Michelle KumbierIndependent DirectorProfile
Edward LiddyIndependent DirectorProfile
John StrattonIndependent DirectorProfile
William OsbornLead Independent DirectorProfile
Hubert JDGeneral VPProfile
Erica BattagliaVP OfficerProfile
Christopher ScogginsSenior Vice President - Rapid DiagnosticsProfile
Michael DaleSenior Vice President - Structural HeartProfile
Sammy KaramSenior Vice President - Established Pharmaceuticals, Emerging MarketsProfile
Michael PedersonSenior Vice President - Electrophysiology and Heart FailureProfile
Lisa EarnhardtExecutive Vice President - Medical DevicesProfile
Alejandro WellischSenior Vice President - Established Pharmaceuticals, Latin AmericaProfile
Christopher CalamariSenior Vice President - U.S. NutritionProfile
Charles BrynelsenSenior Vice President - Abbott VascularProfile
Gregory AhlbergSenior Vice President - Core Laboratory Diagnostics, Commercial OperationsProfile
Philip BoudreauVice President - Finance, ControllerProfile
John GinascolExecutive Vice President - Core DiagnosticsProfile
Michael RomanIndependent DirectorProfile
Mary MorelandExecutive Vice President of Human ResourcesProfile
Sabina EwingSenior OfficerProfile
Randel WoodgriftSenior Vice President - CRMProfile
Elaine LeavenworthVP OfficerProfile
Michael ComillaVice RelationsProfile
Scott LeinenweberAcquisitions LicensingProfile
James YoungVP OfficerProfile
Louis MorroneSenior Vice President - Rapid DiagnosticsProfile
Andrea WainerExecutive Vice President - Rapid and Molecular DiagnosticsProfile
Melissa BrotzVice MarketingProfile

About Abbott Laboratories Management Performance

The success or failure of an entity such as Abbott Laboratories often depends on how effective the management is. Abbott Laboratories management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Abbott management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Abbott management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.14  0.17 
Return On Capital Employed 0.11  0.10 
Return On Assets 0.08  0.12 
Return On Equity 0.15  0.26 
Please note, the imprecision that can be found in Abbott Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Abbott Laboratories. Check Abbott Laboratories' Beneish M Score to see the likelihood of Abbott Laboratories' management manipulating its earnings.

Abbott Laboratories Workforce Analysis

Traditionally, organizations such as Abbott Laboratories use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Abbott Laboratories within its industry.

Abbott Laboratories Manpower Efficiency

Return on Abbott Laboratories Manpower

Revenue Per Employee351.8K
Revenue Per Executive818.6M
Net Income Per Employee50.2K
Net Income Per Executive116.8M
Working Capital Per Employee77.4K
Working Capital Per Executive180.2M

Additional Tools for Abbott Stock Analysis

When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.